SCHEMBL1745189

SCHEMBL1745189

CCOC(=O)CCc1ccc(CN(C)c2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 3/20 0.54
PARP1 P09874 1/20 0.53
KMT2A Q03164 8/20 0.52
MEN1 O00255 6/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NPSR1 Q6W5P4 2/20 0.49
HTT P42858 1/20 0.48
MAPT P10636 4/20 0.46
ALDH1A1 P00352 2/20 0.46
GLA P06280 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CPB1 P15086 1/20 0.46
TSHR P16473 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
CYP4F2 P78329 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746617 0.93 KMT2A (0.50) GSTO1PARP1KMT2AMEN1L3MBTL1
SCHEMBL1746505 0.90 PARP1 (0.48) GSTO1PARP1KMT2AMEN1L3MBTL1
SCHEMBL1747124 0.87 KMT2A (0.58) GSTO1KMT2AMEN1L3MBTL1NPSR1
SCHEMBL1746420 0.86 LTA4H (0.52) GSTO1PARP1KMT2AMEN1NPSR1
SCHEMBL1747118 0.83 KMT2A (0.52) GSTO1PARP1KMT2AMEN1L3MBTL1
SCHEMBL1746563 0.82 KMT2A (0.49) GSTO1KMT2AMEN1L3MBTL1NPSR1
SCHEMBL1744670 0.81 FFAR1 (0.57) KMT2AMEN1L3MBTL1NPSR1HTT
SCHEMBL1746621 0.80 KMT2A (0.60) GSTO1KMT2AMEN1L3MBTL1NPSR1
SCHEMBL18674599 0.79 KMT2A (0.64) GSTO1KMT2AMEN1L3MBTL1NPSR1
SCHEMBL1745362 0.78 NPSR1 (0.48) GSTO1KMT2AMEN1L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GSTO1 3920/4885PARP1 4795/4885KMT2A 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.